FDA approves bictegravir and lenacapavir for HIV - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves bictegravir and lenacapavir for HIV

The treatment was evaluated in patients receiving complex antiretroviral regimens.

  • By

  • Kathryn Wighton

  • August 28, 2026

  • 2 min

Share

Clinical Scorecard: FDA approves bictegravir and lenacapavir for HIV

At a Glance

CategoryDetail
ConditionHIV-1
Key MechanismsBictegravir (integrase strand transfer inhibitor) and lenacapavir (capsid inhibitor)
Target PopulationAdults with HIV-1 RNA levels below 50 copies/mL on a stable antiretroviral regimen
Care SettingOutpatient care for adults with HIV

Key Highlights

  • Bictegravir and lenacapavir approved as a once-daily tablet for HIV-1
  • Approval based on phase 3 ARTISTRY-1 and ARTISTRY-2 trials
  • Regimen showed comparable maintenance of virologic suppression
  • Participants reported improvements in fasting lipid measures and treatment satisfaction
  • Most common adverse reactions: headache, nausea, diarrhea

Guideline-Based Recommendations

Diagnosis

  • Confirm HIV-1 infection and assess HIV-1 RNA levels

Management

  • Switch to bictegravir and lenacapavir for patients with stable virologic suppression

Monitoring & Follow-up

  • Monitor for adverse reactions and treatment efficacy

Risks

  • Contraindicated with dofetilide and strong CYP3A inducers

Patient & Prescribing Data

Adults with HIV-1 on stable antiretroviral therapy

Regimen well tolerated with no new safety concerns identified

Clinical Best Practices

  • Assess for known or suspected resistance before switching regimens
  • Monitor lipid levels and treatment satisfaction post-switch

Related Resources & Content

Original Source(s)

FDA approves bictegravir and lenacapavir for HIV

  • by Kathryn Wighton

  • August 28, 2026

Related Content

First HIV-Positive-to-HIV-Positive Lung Transplant Reported

The procedure was performed under a HOPE Act research protocol at an NYU Langone Health center the institution said is among the limited number of US transplant centers equipped and approved to perform HOPE lung transplants.

Updated COVID Shot Linked to Added Protection

Updated 2025-2026 vaccination was linked to added protection in a CDC-funded analysis that became part of a broader debate over routine vaccine monitoring.

Can LAI-CAB Sustain Long-Term PrEP Use?

A national claims analysis found modest uptake and declining persistence over 2 years despite increasing use of injectable HIV pre-exposure prophylaxis.